Second Annual IBA Conference
May 19 - 21, 2019
La Jolla, California

Keynote Speakers


Dr. Steven Mayo

'Computational protein design: from inception to an AI powered future'

  Steve Mayo is the William K. Bowes Jr. Leadership Chair of the Division of Biology and Biological Engineering and Bren Professor of Biology and Chemistry at the California Institute of Technology in Pasadena, California. He has been a member of the Caltech faculty since 1992 and served as Vice Provost for Research from 2007 to 2010 before becoming Chair of the Division of Biology and Biological Engineering.

Mayo's research focuses on the development of computational approaches to protein engineering – a field that has broad applications ranging from advanced biofuels to human therapeutics.   He co-founded Molecular Simulations Inc (Accelrys, now BIOVIA), a computational chemistry company; Xencor, a publicly traded bio-therapeutics company focused on developing next generation biologics for treating cancer; and, Protabit, a privately held protein engineering company.

Mayo was elected a member of the National Academy of Sciences in 2004 for his pioneering contributions in the field of protein design and was appointed by President Obama in 2013 to the National Science Board. He received his undergraduate degree in chemistry from the Pennsylvania State University, his Ph.D. in chemistry from Caltech, and did postdoctoral work at both UC Berkeley (chemistry) and Stanford (biochemistry).

Sunday, May 19th Opening Evening 



Dr. Stephen Burley

'Recent developments in data deposition, validation, biocuration, and archiving of MX, NMR, and 3DEM structure data in the Protein Data Bank'

Stephen Burley, M.D., D.Phil. is an expert in structural biology, proteomics, bioinformatics, structure/fragment based drug discovery, and clinical medicine/oncology. He currently serves as University Professor and Henry Rutgers Chair, Founding Director of the Institute for Quantitative Biomedicine, and Director of the RCSB Protein Data Bank at Rutgers, The State University of New Jersey. He is also a Member of the Rutgers Cancer Institute of New Jersey, where he Co-Leads the Cancer Pharmacology Research Program. From 2008 to 2012, Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories. Prior to joining Lilly, Burley served as the Chief Scientific Officer and Senior Vice President of SGX Pharmaceuticals, Inc. Until 2002, Burley was the Richard M. and Isabel P. Furlaud Professor at The Rockefeller University and an Investigator in the Howard Hughes Medical Institute. He has authored/coauthored more than 260 scholarly scientific articles.

Monday Afternoon, May 20th


Dr. Tamir Gonen

'MicroED: conception, practice and future opportunities'

  Dr. Gonen is a Member of the Royal Society of New Zealand, a Professor of Biological Chemistry and Physiology at the David Geffen School of Medicine of the University of California, Los Angeles and an Investigator of the Howard Hughes Medical Institute. He is an expert in electron crystallography and cryo EM, determining the 1.9Å resolution structure of the water channel aquaporin-0 by electron crystallography, the highest resolution for any protein determined by cryo EM techniques at the time. Since 2011, Dr. Gonen has worked as a Group Leader at the HHMI Janelia Research Campus where he has continued to work in electron crystallography, pioneering MicroED, a structural biology method with the potential to solve unknown structures at resolutions close to 1Å.  .

Tuesday Morning, May 21st

Presentations and Panels


Monday Morning: Session 1 - Small Molecule Discovery 1

From Abl to EM, a journey in SBDD

Sandra Jacob, Novartis Institute for Biomedical Research

Conformational characterization of non-CDN STING agonists

Charles Lesberg, Merck Research Laboratories

Structure based design of novel inhibitors of the Mcl-1's protein-protein interaction

Xin Huang, Amgen Inc.

Session 2- NMR, Biophysics and Structure

If all models are wrong, how do we find the useful ones?

Martin Scanlon, Monash University

Ligand-dependent structural plasticity of TrkA kinase studied by NMR Spectroscopy 

Reto Horst, Pfizer

Mechanistic characterization and crystal structures of small-molecule inhibitors of E.coli LpxA acyltransferase

Xiaolei Ma, Novartis Institute for Biomedical Research

Monday Afternoon:  Session 3 - Biologics and Protein Design

Structure-based design and optimization of vaccine candidates

Enrico Malito, GlaxoSmithKline Vaccines

Understanding the mechanism of tetravalent biepitopic targeting by determining the 

2.1 A ternary complex structure of OX40 bound to two agonistic fab fragments

Gladys de Leon Boenig, Genentech

Structural characterization of broadly neutralizing influenza antibodies isolated from human and non-human primates

Yu Qiu, Sanofi

Session 4 - Emerging Structural Methods

Water molecules in protein-ligand interfaces

Paul Gibbons, Genentech

ProtaBank: a new database resource for the protein engineering community

Barry Olafson, Protabit, LLC

High-resolution structure determination to support drug discovery

Christopher Arthur, Genentech

Tuesday Morning: Session 5 - Cryo-EM in Drug Discovery

Cryo-EM at Astrazeneca: from molecular mechanisms of drug targets to SBDD

Taiana Maia de Oliveira, Astrazeneca

Cryo-EM resolves the multi-state activation mechanism of TPC channels

Alex Kintzer, Vertex Pharmaceuticals, Inc.

Cryo electron microscopy structures of voltage-gated sodium channels

Alexis Rohou, Genentech

An allosteric mechanism for potent inhibition of human ATP-citrate lyase 

Byron de la Barre, The Consulting Biochemist

Tuesday Afternoon: Session 6 - Small Molecule Drug Discovery 2

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Tom Clayton, Celgene

Structure analysis of Dipeptidyl peptidases DPP8 and DPP9 reveal inhibitor- and substrate-binding mode and cooperativity

Stephan Krapp, Proteros

Delineating the mechanism of the anti-cancer natural product nimbolide

Dirksen Bussiere, Novartis Institutes for Biomedical Research

Session 7 - X-ray Technology

Crystallography at the Advanced Light Source: current status and future opportunities

Corie Ralston, Advanced Light Source

Automated, remote controlled protein to structure pipelines for drug design

Jose Antonio Marquez, European Molecular Biology Laboratory (EMBL)

Integrated structural biology platform at Diamond Light Source

Elizabeth Shotton, Diamond Light Source

De novo protein structure phasing for challenging targets

Hui Wang, Takeda

New opportunities at SSRL and LCLS for data collection and diffraction quality optimization under humidity controlled conditions

Aina Cohen, SSRL-SMB, SLAC National Accelerator Laboratory    

Additional Presentations

Structural insights into inhibition of class I HDACs with novel zinc binding and nonbinding inhibitors

Daniel Klein, Merck

Structure determination of a novel dextran binding module in complex with isomaltohexaose 

Yong Wang, Eli Lilly and Company

Biophysical characterization and structural studies of Small Multidrug Resistance family of transporters

Ali Kermani, University of Michigan

Development of a virtual reality platform for effective communication of structural data in drug discovery

Steve McCloskey, Nanome

Second-harmonic generation (SHG) – A novel on-target and high-throughput technology for small molecule screening by detecting structural changes of target biomolecules

Margaret Butko, Biodesy, Inc.

Protein domain trapping: high throughput protein engineering to enable biophysics and structural biology based drug discovery

Denys Pogoryelov, Zobio BV

NanoImaging Services, Inc. – a one-stop solution for outsourcing CryoEM

Annete Schneemann, NanoImaging Services, Inc.

Canadian Macromolecular Crystallography Facility (CMCF) upgrades: enabling higher flux and micro-focusing for versatile high-throughput MX studies

Michel Fodje, Canadian Light Source Inc.

Emerging technologies and X-ray crystallography (it's hard to get a crystal structure without a crystal)

Andrew Bond, DeNovX

Fast molecular interaction screening of epigenetic gene regulator HMT G9a with fragments from a large chemical space using the Dianthus NT.23PicoDuo

Lindsay Dawson, NanoTemper Technologies

Wuxi Biortus: a cryo-EM CRO company for drug discovery in China 

Lei Jin, Wuxi Biortus Biosciences Co., Ltd.

Crystal structures of human phospholipases enable pharmacological characterization of isoenzyme selectivity

Claire Metrick, Biogen, Inc. 

Structural insights into an intracellular target for cancer immunology - HPK1

Weiru Wang, Genentech  

Monday Panel

Protein Design for Structure Determination of Membrane Proteins and Large Complexes

Protein preparation for structure biology in industrial settings is in transition as new techniques are introduced.  Our panel will discuss differences in protein requirements for X-ray crystallography versus Cryo-EM, stabilization techniques for membrane proteins maintaining the functional state, data bases as tool to efficient construct design, and offer attendees to ask detailed questions regarding upscale and purification approaches, most useful analytical equipment and new developments in supporting software. 


Sujata Sharma (Janssen Research & Development) - Moderator 

Kathleen Aertgeerts (Vertex Pharmaceuticals) 

Aaron Thompson (Janssen Research & Development)

Byron DeLaBarre (The Consulting Biochemist)


Anatrace / Molecular Dimensions 

Tuesday Panel

Emerging X-Ray Technologies for Structural Biology

There are a wide range of new technologies and techniques now available to explore the connections between protein structure and function. The recent availability of bright X-ray microbeams and advanced automation at synchrotrons, the use of high-speed pixel array detectors for diffraction and Cryo-EM measurements, and the advent of X-ray Free Electron Lasers (XFELs), has enabled the examination of biological systems that were previously inaccessible.  Such procedures such as room temperature serial crystallography on nano-crystals, in-situ crystallization and diffraction screening, controlled dehydration and on-site integration of X-ray results with Cryo-EM are now becoming readily available to the industrial community. The panel will discuss how these advances will benefit the structural biologist in a drug discovery setting and will answer attendees' questions on where they see these multiple developments taking the industrial user in the future. 


Aina Cohen (Stanford Synchrotron Radiation Lightsource) - Moderator

Michel Fodje, (Canadian Light Source)

Ashley Deacon, (Accelero Biostructures)

Corie Ralston, (Berkeley Center for Structural Biology)

Eddie Snell (NSF BioXFEL Science and Technology Center)